Product Images Rizatriptan Benzoate

This is a medicine bottle label for Rizatriptan Benzoate, 10mg tablets, with NDC number 3172246306. It warns to keep it out of the reach of children. It also lists the manufacturer as Cambe Pharmaceutis, with an address in Piscataway, NJ. The label includes several repetitions of the same text.*

This is a product description for Rizatriptan Benzoate Tablets. Each pack contains 18 unit-dose tablets in blister cards of six tablets each, with each tablet containing 5mg of medicine. The pharmacists are advised to dispense the patient information leaflet to each patient. The text also contains some reference numbers and codes, which might not be useful for a general description.*

The text is about a medication called Rizatriptan Benzoate in tablet form with a strength of 5 mg. The text displays various warnings related to medication and the manufacturer (or distributors) identified by the code NDC 3172246206. There are also references to dosage instructions and contraindications, but the output is not clear.*

Figure 1 shows the estimated probability of achieving an initial headache response by 2 hours in pooled studies 1, 2, 3 and 4, with different doses of Rizatriptan Benzoate tablets. The graph demonstrates the percentage of participants who experienced some relief from their headache with the medication at each time point, up to 4 hours after taking it. It also shows that a higher dose corresponds to a higher response rate.*

This is a figure showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate for migraines over a 24 hours period after the initial dose of treatment. The data is obtained from pooled studies 1, 2, 3, and 4. The graph shows the estimated probability of remedication or rescue at different time intervals (in hours) after dosing, and the y-axis represents this probability.*

This table shows the incidence of adverse reactions in adults after taking a single dose of either Rizatriptan Benzoate Tablets or Placebo. The adverse reactions are separated into categories, including atypical sensations, pain and pressure sensations, gastrointestinal, neurological, and others. The percentage of patients experiencing each adverse reaction is shown for each dosage. For example, for patients taking 5mg of Rizatriptan Benzoate Tablets, 1% experienced atypical sensations, 3% experienced paresthesia, and 6% experienced pain and other pressure sensations.*

The text provides response rates 2 hours after treating an initial headache with placebo and Rizatriptan benzoate tablets in four different studies. The results indicate that the percentage of patients who reported relief from headache was significantly higher with Rizatriptan benzoate compared to placebo in all studies. The effectiveness of Rizatriptan benzoate was also compared to a 5mg dose, which showed no significant difference. These results are only for the initial headache and a p-value of less than 0.05 was considered significant.*